AnaptysBio, Inc. (ANAB) vs Rapport Therapeutics, Inc. Common Stock (RAPP)

A side-by-side comparison of AnaptysBio, Inc. and Rapport Therapeutics, Inc. Common Stock across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
AnaptysBio, Inc. logo
ANAB
AnaptysBio, Inc.
$1.42B
$47.89HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Rapport Therapeutics, Inc. Common Stock logo
RAPP
Rapport Therapeutics, Inc. Common Stock
$1.49B
$31.15HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — ANAB vs RAPP

growth of $100 · dividends reinvested · last 2y
ANAB +196.2% (+72.1%/yr)RAPP +54.8% (+24.4%/yr)ANAB compounded faster over this window
100200300400Start $10020252026$296$155
ANAB RAPP

ANAB vs RAPP: by the numbers

  • •RAPP is the larger company ($1.49B vs $1.42B market cap).
  • •ANAB is profitable (82.37% net margin) while RAPP runs a net loss (-685.80%).

Metrics side by side

Valuation

MetricANABRAPP
P/E ratio8.92N/A
P/S ratio5.9774.49
P/B ratio133.963.52
EV / EBITDA11.44N/A
FCF yield1.27%N/A

Profitability

MetricANABRAPP
Gross margin98.97%0.00%
Operating margin20.42%0.00%
Net margin82.37%-685.80%
ROE1849.06%-32.43%
ROIC47.55%-35.66%

Growth (annualized)

MetricANABRAPP
Revenue CAGR (5Y)18.60%N/A
FCF CAGR (5Y)27.41%N/A
Total return CAGR (5Y)21.54%N/A

Frequently asked

Is ANAB or RAPP more profitable?
ANAB runs the higher net margin — ANAB at 82.37% versus RAPP at -685.80%.

Go deeper

Full ANAB analysisFull RAPP analysisInteractive comparison tool

Dig into the metrics

AnaptysBio P/E ratioAnaptysBio ROERapport Therapeutics, Inc. Common Stock ROEAnaptysBio operating marginRapport Therapeutics, Inc. Common Stock operating marginAnaptysBio revenue growthRapport Therapeutics, Inc. Common Stock revenue growthAnaptysBio free cash flowRapport Therapeutics, Inc. Common Stock free cash flow

AnaptysBio & Rapport Therapeutics, Inc. Common Stock appear in these rankings

Fastest Revenue Growth StocksHighest ROE StocksHighest ROIC StocksLowest P/E Ratio Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.